Add-on to metformin in T2DM—linagliptin or glimepiride?

被引：0
|
作者：
Mikkel Christensen
Filip K. Knop
机构：
[1] Bispebjerg Hospital,Department of Clinical Pharmacology
[2] University of Copenhagen,Diabetes Research Division, Department of Internal Medicine
[3] Gentofte Hospital,undefined
[4] University of Copenhagen,undefined
来源：
Nature Reviews Endocrinology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding between one of the most commonly used second-line agents, glimepiride, and the recently approved dipeptidyl peptidase 4 inhibitor linagliptin.
引用
收藏
页码：576 / 578
页数：2
相关论文
共 50 条
  • [1] DIABETES Add-on to metformin in T2DM-linagliptin or glimepiride?
    Christensen, Mikkel
    Knop, Filip K.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (10) : 576 - 578
  • [2] Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-on to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)
    Ridderstrale, Martin
    Andersen, Knut Robert
    Zeller, Cordula
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A70 - A70
  • [3] Empaglifl ozin (EMPA) Compared with Glimepiride (GLIM) as Add-On to Metformin (MET) for 4 Years in Patients with Type 2 Diabetes (T2DM)
    Ridderstrale, Martin
    Robert, Knut
    Toorawa, Andersen
    Woerle, Hans J.
    Salsali, Afshin
    [J]. DIABETES, 2016, 65 : A47 - A48
  • [4] Ramate as add-on to metformin (MET) in obese subjects with type 2 diabetes (T2DM)
    Toplak, H
    Vercruysse, F
    Sun, X
    Fitchet, M
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S159 - S159
  • [5] Efficacy and Safety of Saxagliptin Add-on to Metformin Compared with Acarbose Add-on to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Monotherapy
    Du, Jin
    Liang, Li
    Fang, Hui
    Xu, Fengmei
    Li, Wei
    Shen, Liya
    Mu, Yiming
    [J]. DIABETES, 2016, 65 : A293 - A293
  • [6] Empagliflozin as Add-on to Linagliptin and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Region in a 24-Week Randomized Trial
    Wanner, Christoph
    Naderali, Ebrahim
    Maldonaldo, Mario
    Del Parigi, Angelo
    Toorawa, Robert
    Lee, Christopher
    [J]. DIABETES, 2016, 65 : A288 - A289
  • [7] Economic Evaluation of Dapagliflozin as Add-On to Metformin in T2DM in the Israeli Health Care Setting
    Moshel, Shai
    Vexberg, Michal Hirsch
    Shavit, Oren
    Toledano, Yoel
    [J]. DIABETES, 2018, 67
  • [8] ECONOMIC EVALUATION OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR T2DM TREATMENT IN THE ISRAELI HEALTHCARE SETTING
    Moshel, S.
    Vexberg, Hirsch M.
    Shavit, O.
    Toledano, Y.
    [J]. VALUE IN HEALTH, 2018, 21 : S131 - S131
  • [9] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A278 - A278
  • [10] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
12345